Article

Carmat has entered judicial liquidation and withdrawn from the stock exchange after being placed under judicial recovery, with a transfer plan approved for Carmat SAS to continue operations. Meanwhile, Genfit reported positive Phase 1 results for its experimental drug G1090N, showing a favorable safety profile and anti-inflammatory activity. Additionally, GTT received an order from Hanwha Ocean for cryogenic tanks for LNG carriers, while Hoffmann Green Cement Technologies prepares to announce its Q4 revenue.